Quarterly report pursuant to Section 13 or 15(d)

EQUITY TRANSACTION (Details Narrative)

v3.21.2
EQUITY TRANSACTION (Details Narrative) - USD ($)
1 Months Ended 3 Months Ended
Mar. 09, 2021
Apr. 30, 2019
Mar. 31, 2021
Jul. 31, 2021
Oct. 31, 2021
Jun. 17, 2021
Apr. 30, 2021
Oct. 31, 2020
Jul. 28, 2020
Class of Stock [Line Items]                  
Preferred Stock, Shares Authorized         10,000,000   10,000,000    
Preferred Stock, Par or Stated Value Per Share         $ 0.0001   $ 0.0001    
Warrant terms         3 years 1 month 6 days        
Warrant [Member]                  
Class of Stock [Line Items]                  
Warrant terms         5 years     5 years  
Exercise price (in dollars per share)         $ 6.25 $ 6.25     $ 3.00
A L S F [Member]                  
Class of Stock [Line Items]                  
Shares purchase price   15,000,000              
Warrant terms   12 months              
Securities Purchase Agreements [Member] | A L S F [Member]                  
Class of Stock [Line Items]                  
Number of shares purchase   10,000,000              
Shares purchase price   15,000,000              
Shares purchase price (in dollars per share)   $ 1.50              
Securities Purchase Agreements [Member] | A L S F [Member] | Warrant [Member]                  
Class of Stock [Line Items]                  
Number of shares purchase   5,000,000              
Warrant terms   5 years              
Exercise price (in dollars per share)   $ 3.00              
Securities Purchase Agreements [Member] | Digital Power Lending [Member]                  
Class of Stock [Line Items]                  
Number of shares issued     6,666,667            
Proceeds from sale of equity     $ 10,000,000            
Shares issued price per share     $ 1.50            
Proceeds from related party $ 4,000,000                
Advance from related parties $ 1,800,000                
Description of purchase agreement terms     DPL (i) purchased an additional 1,333,333 shares of Common Stock upon approval by the FDA of the Company’s IND for its Phase Ia clinical trials for AL001 for a purchase price of $2 million, and (ii) will purchase 2,666,667 shares of Common Stock upon the completion of these Phase Ia clinical trials for AL001 for a purchase price of $4 million. The Company further agreed to issue to DPL warrants to purchase a number of shares of Common Stock equal to 50% of the shares of Common Stock purchased under the securities purchase agreement at an exercise price of $3.00 per share            
Securities Purchase Agreements [Member] | Digital Power Lending [Member] | Final Tranche [Member]                  
Class of Stock [Line Items]                  
Additional right to invest     $ 10,000,000 $ 10,000,000          
Securities Purchase Agreements [Member] | Ault Global [Member] | Convertible Promissory Note [Member]                  
Class of Stock [Line Items]                  
Number of shares issued 2,666,667                
Shares value surrender for cancellation $ 50,000                
Series A Preferred Stock [Member]                  
Class of Stock [Line Items]                  
Preferred Stock, Shares Authorized         8,640,000        
Preferred Stock, Par or Stated Value Per Share         $ 0.0001   $ 0.0001    
Preferred Stock Shares Designated         1,360,000   1,360,000